Bulletin
Investor Alert

bluebird bio Inc.

NAS: BLUE

GO
/marketstate/country/us

After Hours

/zigman2/quotes/207450173/composite

$

28.05

Change

-0.35 -1.23%

Volume

Volume 36,380

May 10, 2021, 7:50 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/207450173/composite

Today's close

$ 30.48

$ 28.40

Change

-2.08 -6.82%

Day low

Day high

$28.23

$30.35

Open
Open: 30.31

52 week low

52 week high

$24.24

$72.51

Open

Market cap

$2.06B

Average volume

1.66M

P/E ratio

N/A

Rev. per Employee

$206,706

EPS

-9.38

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/blue

MarketWatch News on BLUE

  1. Bluebird Shares Jump as FDA Approves Cancer Therapy

    9:00 a.m. March 29, 2021

    - Barron's Online

  2. Bluebird Bio stock price target raised to $70 vs. $69 at Mizuho

    7:00 a.m. March 29, 2021

    - Ciara Linnane

  3. Bluebird bio upgraded to buy from neutral at Mizuho

    7:39 a.m. March 11, 2021

    - Tomi Kilgore

  4. Bluebird bio stock price target raised to $69 from $34 at Mizuho

    7:39 a.m. March 11, 2021

    - Tomi Kilgore

  5. Bluebird bio stock price target raised to $69 from $34 at Mizuho

    11:53 a.m. March 10, 2021

    - Tomi Kilgore

  6. Bluebird bio upgraded to buy from neutral at Mizuho

    11:53 a.m. March 10, 2021

    - Tomi Kilgore

  7. Bluebird bio downgraded to neutral from overweight at J.P. Morgan

    9:33 a.m. Feb. 17, 2021

    - Tomi Kilgore

  8. Bluebird bio stock price target cut to $39 from $76 at J.P. Morgan

    9:33 a.m. Feb. 17, 2021

    - Tomi Kilgore

  9. Bluebird bio downgraded to neutral from buy at Mizuho

    2:07 p.m. Feb. 16, 2021

    - Tomi Kilgore

  10. Bluebird bio stock price target cut to $34 from $123 at Mizuho

    2:07 p.m. Feb. 16, 2021

    - Tomi Kilgore

  11. Gene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programs

    9:12 a.m. Jan. 11, 2021

    - Barron's Online

  12. Bluebird Bio downgraded to hold from buy at Maxim Group

    10:12 a.m. Dec. 9, 2020

    - Tomi Kilgore

  13. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/blue

Other News on BLUE

  1. Bluebird Bio (BLUE) Receives a Buy from Canaccord Genuity

    6:37 a.m. May 7, 2021

    - SmarterAnalyst

  2. Bluebird Bio (BLUE) Receives a Hold from BMO Capital

    11:07 a.m. May 6, 2021

    - SmarterAnalyst

  3. William Blair Keeps a Hold Rating on Bluebird Bio (BLUE)

    4:48 a.m. May 6, 2021

    - SmarterAnalyst

  4. 10-Q: BLUEBIRD BIO, INC.

    4:29 p.m. May 5, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  5. Checking In on 3 Stock Samplers

    5:59 p.m. May 3, 2021

    - Motley Fool

  6. What's in the Cards for Bristol-Myers (BMY) Q1 Earnings?

    2:29 p.m. April 23, 2021

    - Zacks.com

  7. Cryoport: Once In A Lifetime Opportunity

    1:42 p.m. April 22, 2021

    - Seeking Alpha

  8. Leerink Partners Thinks Bluebird Bio’s Stock is Going to Recover

    8:08 a.m. April 22, 2021

    - SmarterAnalyst

  9. Anthem's (ANTM) Q1 Earnings Beat Estimates, Increase Y/Y

    11:42 a.m. April 21, 2021

    - Zacks.com

  10. Tenet Healthcare's (THC) Q1 Earnings Surpass, Improve Y/Y

    11:41 a.m. April 21, 2021

    - Zacks.com

  11. Loading more headlines...
/news/pressrelease/company/us/blue

Press Releases on BLUE

  1. Gene Therapy Market Size to Record US$ 15.0 Bn through 2030

    5:53 a.m. Today

    - Market Stats News

  2. bluebird bio Announces May Investor Events

    8:00 a.m. May 3, 2021

    - BusinessWire - BZX

  3. T-cell Therapy Market Size, Share, Trends, Analysis and Forecast 2027

    7:15 a.m. April 30, 2021

    - Market Insight Reports

  4. Gene Therapy Market: Global Industry Analysis and Forecast 2021-2026

    8:39 a.m. April 27, 2021

    - Market Insight Reports

  5. Genome Engineering Market Analysis And Growth Rate to 2027 With Market Players

    6:59 a.m. April 27, 2021

    - Market Insight Reports

  6. Loading more headlines...

Rates »

Link to MarketWatch's Slice.